Nasdaq:HBIO
HARVARD BIOSCIENCE INC
A leading North American manufacturer of laboratory equipment serving life science research and education markets with a diverse product portfolio.
Key Metrics
Investment Thesis
Bull Case
The company holds an established market position in the essential life sciences sector with a diverse product range that offers defensive characteristics against economic downturns. Potential for operational restructuring could resolve current losses, turning the significant R&D investment of $10.4M into profitable new products or improved margins. The strong brand equity and loyal customer base in academia provide a stable foundation for future recovery if market conditions improve.
Bear Case
Persistent net losses totaling over $25M across the last three years demonstrate an inability to generate sustainable profitability despite steady revenue streams. The massive accumulated deficit of -$158.0M and current debt obligations of $37.4M create significant financial distress risks that could lead to insolvency or dilutive capital raising events. Declining year-over-year revenue suggests a shrinking addressable market or loss of competitive advantage, making the business model vulnerable in a cost-sensitive global economy.
About HARVARD BIOSCIENCE INC
Harvard Bioscience, Inc. designs and manufactures laboratory equipment and supplies primarily serving life science research markets. The company provides critical tools such as microscopes, centrifuges, and incubators to academic institutions, pharmaceutical companies, and government laboratories globally. With a strong focus on educational and professional lab solutions, the firm addresses the needs of researchers in biology, chemistry, and medical sciences.
Analysis
Management Discussion
Despite generating $94.1M in revenue, the company reported a net loss of $12.4M in 2024, marking a deterioration from a $3.4M loss in 2023 after a better $9.5M loss in 2022. Operating expenses surged to $61.0M while operating profit turned negative at -$6.2M, suggesting that cost structures are not scaling with the declining revenue base. Cash reserves of $4.1M combined with net cash outflows from investing and financing activities indicate a tightening liquidity position that requires careful monitoring by stakeholders.
Industry Overview
The laboratory equipment industry is cyclical and driven by government funding levels, academic enrollment trends, and biotechnology R&D spending which are currently facing headwinds. Competition from international manufacturers with lower production costs exerts downward pressure on pricing and margins for established players like this company. Regulatory changes in healthcare and research funding allocations significantly impact demand forecasts and inventory planning for suppliers of scientific instruments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $113.3M | $112.2M | $94.1M |
| Cost of Revenue | $52.5M | $46.2M | $39.4M |
| Gross Profit | $60.8M | $66.1M | $54.8M |
| Operating Expenses | $67.8M | $64.2M | $61.0M |
| Operating Income | $-6.9M | $1.9M | $-6.2M |
| R&D | $12.3M | $11.8M | $10.4M |
| G&A | $24.5M | $22.8M | $21.5M |
| Marketing | $25.0M | $24.1M | $22.2M |
| Stock-Based Comp | $4.4M | $5.0M | $4.3M |
| Depreciation | $1.5M | $1.5M | $1.7M |
| Amortization | $6.1M | $5.5M | $5.3M |
| Other OpEx | $5.9M | $5.5M | $6.9M |
| Non-Operating Income | $-2.2M | $-4.5M | $-5.5M |
| Pre-Tax Income | $-9.2M | $-2.6M | $-11.7M |
| Income Tax | $337.0K | $859.0K | $740.0K |
| Continuing Ops | $-9.5M | $-3.4M | $-12.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-9.5M | $-3.4M | $-12.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-9.5M | $-3.4M | $-12.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $51.1M | $49.0M | $45.1M |
| Cash & Equivalents | $4.5M | $4.3M | $4.1M |
| Accounts Receivable | $16.7M | $16.1M | $14.9M |
| Inventory | $26.4M | $24.7M | $23.2M |
| Other Current Assets | $3.5M | $3.9M | $2.9M |
| Long-Term Assets | $94.2M | $88.3M | $81.5M |
| PP&E (Net) | $3.4M | $4.0M | $5.1M |
| Intangibles | $21.0M | $16.0M | $11.1M |
| Goodwill | $56.3M | $57.1M | $56.3M |
| Operating Leases | $5.8M | $4.8M | $6.1M |
| Other LT Assets | $7.8M | $6.5M | $2.8M |
| Total Assets | $145.4M | $137.4M | $126.6M |
| Current Liabilities | $23.2M | $26.5M | $55.0M |
| Accounts Payable | $6.4M | $5.6M | $4.8M |
| Current Debt | $4.1M | $6.1M | $37.4M |
| Current Leases | $2.1M | $1.4M | $1.2M |
| Deferred Revenue | $3.4M | $4.5M | $3.8M |
| Taxes Payable | $0 | — | — |
| Other Current Liab | $7.2M | $8.9M | $7.9M |
| Long-Term Liabilities | $49.9M | $37.8M | $8.3M |
| Long-Term Debt | $43.0M | $30.7M | $0 |
| LT Operating Leases | $5.3M | $4.8M | $6.4M |
| Other LT Liab | $1.6M | $2.3M | $2.0M |
| Total Liabilities | $73.1M | $64.3M | $63.3M |
| Shareholders' Equity | $72.2M | $73.1M | $63.3M |
| Retained Earnings | $-142.2M | $-145.6M | $-158.0M |
| AOCI | $-15.1M | $-14.2M | $-15.7M |
| Total L&E | $145.4M | $137.4M | $126.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-9.5M | $-3.4M | $-12.4M |
| Non-Cash Adjustments | $15.1M | $20.8M | $18.9M |
| Working Capital Changes | $-4.4M | $-3.4M | $-5.0M |
| Cash from Operations | $1.2M | $14.0M | $1.4M |
| Capital Expenditures | $1.6M | $1.8M | $2.6M |
| Cash from Investing | $-1.6M | $-1.8M | $-1.3M |
| Debt Repayments | $3.2M | $4.1M | $6.0M |
| Cash from Financing | $-2.8M | $-12.1M | $-131.0K |
| FX Effect | $-38.0K | $-320.0K | $-140.0K |
| Net Change in Cash | $-3.3M | $-225.0K | $-175.0K |
| Beginning Cash | $7.8M | $4.5M | $4.3M |
| Ending Cash | $4.5M | $4.3M | $4.1M |
Frequently Asked Questions
How does HARVARD BIOSCIENCE INC make money?
The company operates through three primary revenue streams: Microscopy products including microscopes and imaging systems; General laboratory equipment covering centrifuges, incubators, and environmental chambers; and Laboratory supplies encompassing consumables, software solutions, and specialized accessories for scientific workflows.
What are the main risks for HBIO?
Significant operating losses of $12.4M in 2024 raise concerns about liquidity and the ability to sustain operations without substantial external financing. Revenue contraction from $113.3M in 2022 to $94.1M in 2024 indicates potential market saturation, pricing pressure, or competitive erosion of market share. The company carries a large current portion of long-term debt at $37.4M which represents a substantial liability given the negative cash flow from operations and financing activities. Dependence on global supply chains for manufacturing components exposes the business to geopolitical instability and raw material cost fluctuations.
What is HBIO's competitive advantage?
Strong brand recognition and long-standing relationships with academic institutions and research centers create high switching costs and customer loyalty. The company leverages a broad product portfolio that allows it to cross-sell complementary items within a single laboratory setup. Established distribution networks in the United States, Europe, and Asia provide efficient access to key market segments.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.